TG THERAPEUTICS, INC. (TGTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$57.02

From 52W high−3.71%

Volume4.80M

Market cap$8.71B

P/E (TTM)18.7x

P/S (TTM)10.9x

Div yield—

Key dataSep 18, 2026

Open

$57.02

From 52W high

−3.71%

Volume

4.80M

Market cap

$8.71B

ValuationView details →

P/E (Fwd)

30.0x

EV/EBITDA

66.4x

P/E (TTM)

18.7x

RSI (14)

60.0

MomentumView details →

1D Return

+0.71%

YTD Return

+91.41%

SummaryUpdated Jun 1, 2026

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company founded in 1993 and headquartered in New York. The company focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. After decades of research and development, TG Therapeutics achieved its first major commercial milestone in December 2022 with FDA approval of <b>BRIUMVI</b>, a novel treatment for relapsing forms of multiple sclerosis. The company has since transitioned from a pure development-stage biotech to a commercial enterprise with significant revenue growth, generating over $329 million in 2024.

Ask drillr about TG THERAPEUTICS, INC. →

ValuationView details →

P/E (Fwd)

30.0x

P/E (TTM)

18.7x

EV/EBITDA

66.4x

EV/Sales

11.1x

P/S (TTM)

10.9x

P/B (TTM)

14.4x

ProfitabilityView details →

Gross Margin

82.36%

Net Margin

55.22%

EBITDA Margin

16.78%

ROE (TTM)

73.08%

ROA (TTM)

26.93%

Asset Turnover

0.50x

GrowthView details →

Revenue YoY

+76.08%

EPS YoY

+634.60%

FCF YoY

+99.05%

Revenue CAGR 3Y

+504.86%

EPS CAGR 3Y

+489.19%

EBITDA YoY

+37.30%

MomentumView details →

1D Return

+0.71%

YTD Return

+91.41%

1Y Return

+76.27%

RSI (14)

60.0

vs 50D SMA

+6.75%

vs 200D SMA

+42.43%

Capital & dividendView details →

Debt/Equity

1.25x

Current Ratio

4.27x

Quick Ratio

3.72x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.05

EPS Surprise

−83.64%

Beats (12Q)

5/12

Next Q EPS Est

$0.35

Avg Surprise (4Q)

−29.56%

Rev Surprise

4.60%

Financials snapshotView financials →

Revenue (TTM)

799.54M

Net Income (TTM)

441.49M

Op. CF (TTM)

−18000.00

Next earningsNov 2, 2026 →

Latest newsMore news →

Deutsche Bank AG acquired a new stake of 235,481 shares in TG Therapeutics, Inc., valued at approximately $12.9 million, as disclosed in a Form 13F filing.28d ago

TG Therapeutics announced its financial results for the second quarter of 2026, reporting total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million.48d ago

Similar companies

Ascletis Pharma Inc.01672.HK Vaxcyte, Inc.PCVX ST诺泰688076.SH Caris Life Sciences, Inc.CAI ImmunityBio, Inc.IBRX 中源协和600645.SH Find similar companies →

Latest newsMore news →

Deutsche Bank AG acquired a new stake of 235,481 shares in TG Therapeutics, Inc., valued at approximately $12.9 million, as disclosed in a Form 13F filing.28d ago TG Therapeutics announced its financial results for the second quarter of 2026, reporting total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million.48d ago